Angela Michelle Reiersen

Dr. Angela Michelle Reiersen

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2021 in Molecular Psychiatry
Verified
Journal Article
Closed access
PDF file
NHNicolas Hoertel
Nicolas Hoertel
MSMarina Sánchez-Rico
Marina Sánchez-Rico
CCCéline Cougoule
Céline Cougoule
EGErich Gulbins
Erich Gulbins
JKJohannes Konrhuber
Johannes Konrhuber
FLFrédéric Limosin
Frédéric Limosin

1 December 2021 in Drugs
Verified
Journal Article
Open access
PDF file
SFShelley Facente
Shelley Facente
ARAngela Michelle Reiersen
Angela Michelle Reiersen
ELEric J. Lenze
Eric J. Lenze
DBDavid Boulware
David Boulware
JKJeffrey D. Klausner
Jeffrey D. Klausner
SARS-CoV-2 infection causes COVID-19, which frequently leads to clinical deterioration and/or long-lasting morbidity. Academic and governmental experts thr

5 October 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
NHNicolas Hoertel
Nicolas Hoertel
MSMarina Sánchez-Rico
Marina Sánchez-Rico
JKJohannes Konrhuber
Johannes Konrhuber
EGErich Gulbins
Erich Gulbins
ARAngela Michelle Reiersen
Angela Michelle Reiersen
OCon behalf of AP-HP/Université Paris Cité/INSERM COVID-19 Research Collaboration, AP-HP COVID CDR Initiative and “Entrepôt de Données de Santé” AP-HP Consortium
on behalf of AP-HP/Université Paris Cité/INSERM COVID-19 Research Collaboration, AP-HP COVID CDR Initiative and “Entrepôt de Données de Santé” AP-HP Consortium
To reduce Coronavirus Disease 2019 (COVID-19)-related mortality and morbidity, widely available oral COVID-19 treatments are urgently needed. Certain antidepressants, such as fluvoxamine or fluoxetine, may be beneficial against COVID-19. We included 388,945 adult inpatients who tested positive for SARS-CoV-2 at 36 AP–HP (Assistance Publique–Hôpitaux de Paris) hospitals from 2 May 2020 to 2 November 2021. We compared the prevalence of antidepressant use at admission in a 1:1 ratio matched analytic sample with and without COVID-19 (N = 82,586), and assessed its association with 28-day all-cause mortality in a 1:1 ratio matched analytic sample of COVID-19 inpatients with and without antidepressant use at admission (N = 1482). Antidepressant use was significantly less prevalent in inpatients with COVID-19 than in a matched control group of inpatients without COVID-19 (1.9% versus 4.8%; Odds Ratio (OR) = 0.38; 95%CI = 0.35–0.41, p < 0.001). Antidepressant use was significantly associated with reduced 28-day mortality among COVID-19 inpatients (12.8% versus 21.2%; OR = 0.55; 95%CI = 0.41–0.72, p < 0.001), particularly at daily doses of at least 40 mg fluoxetine equivalents. Antidepressants with high FIASMA (Functional Inhibitors of Acid Sphingomyelinase) activity seem to drive both associations. These treatments may reduce SARS-CoV-2 infections and COVID-19-related mortality in inpatients, and may be appropriate for prophylaxis and/or COVID-19 therapy for outpatients or inpatients.

22 August 2022 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
BFBradley A. Fritz
Bradley A. Fritz
NHNicolas Hoertel
Nicolas Hoertel
ELEric J. Lenze
Eric J. Lenze
FJFarid Jalali
Farid Jalali
ARAngela Michelle Reiersen
Angela Michelle Reiersen
Antidepressants have previously been associated with better outcomes in patients hospitalized with COVID-19, but their effect on clinical deterioration among ambulatory patients has not been fully explored. The objective of this study was to assess whether antidepressant exposure was associated with reduced emergency department (ED) or hospital visits among ambulatory patients with SARS-CoV-2 infection. This retrospective cohort study included adult patients (N = 25 034) with a positive SARS-CoV-2 test performed in a non-hospital setting. Logistic regression analyses tested associations between home use of antidepressant medications and a composite outcome of ED visitation or hospital admission within 30 days. Secondary exposures included individual antidepressants and antidepressants with functional inhibition of acid sphingomyelinase (FIASMA) activity. Patients with antidepressant exposure were less likely to experience the primary composite outcome compared to patients without antidepressant exposure (adjusted odds ratio [aOR] 0.89, 95% CI 0.79–0.99, p = 0.04). This association was only observed with daily doses of at least 20 mg fluoxetine-equivalent (aOR 0.87, 95% CI 0.77–0.99, p = 0.04), but not with daily doses lower than 20 mg fluoxetine-equivalent (aOR 0.94, 95% CI 0.80–1.11, p = 0.48). In exploratory secondary analyses, the outcome incidence was also reduced with exposure to selective serotonin reuptake inhibitors (aOR 0.87, 95% CI 0.75–0.99, p = 0.04), bupropion (aOR 0.70, 95% CI 0.55–0.90, p = 0.005), and FIASMA antidepressant drugs (aOR 0.87, 95% CI 0.77–0.99, p = 0.03). Antidepressant exposure was associated with a reduced incidence of emergency department visitation or hospital admission among SARS-CoV-2 positive patients, in a dose-dependent manner. These data support the FIASMA model of antidepressants’ effects against COVID-19.

3 February 2023 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
YIYukitoshi Izumi
Yukitoshi Izumi
ARAngela Michelle Reiersen
Angela Michelle Reiersen
ELEric J. Lenze
Eric J. Lenze
SMSteven Mennerick
Steven Mennerick
CZCharles Zorumski
Charles Zorumski
Certain selective serotonin reuptake inhibitors (SSRIs) have anti-inflammatory effects in preclinical models, and recent clinical studies suggest that fluvoxamine can prevent deterioration in patients with COVID-19, possibly through activating sigma 1 receptors (S1Rs). Here we examined potential mechanisms contributing to these effects of fluvoxamine and other SSRIs using a well-characterized model of pro-inflammatory stress in rat hippocampal slices. When hippocampal slices are exposed acutely to lipopolysaccharide (LPS), a strong pro-inflammatory stimulus, basal synaptic transmission in the CA1 region remains intact, but induction of long-term potentiation (LTP), a form of synaptic plasticity thought to contribute to learning and memory, is completely disrupted. Administration of low micromolar concentrations of fluvoxamine and fluoxetine prior to and during LPS administration overcame this LTP inhibition. Effects of fluvoxamine required both activation of S1Rs and local synthesis of 5-alpha reduced neurosteroids. In contrast, the effects of fluoxetine did not involve S1Rs but required neurosteroid production. The ability of fluvoxamine to modulate LTP and neurosteroid production was mimicked by a selective S1R agonist. Additionally, fluvoxamine and fluoxetine prevented learning impairments induced by LPS in vivo. Sertraline differed from the other SSRIs in blocking LTP in control slices likely via S1R inverse agonism. These results provide strong support for the hypothesis that S1Rs and neurosteroids play key roles in the anti-inflammatory effects of certain SSRIs and that these SSRIs could be beneficial in disorders involving inflammatory stress including psychiatric and neurodegenerative illnesses.

17 March 2021 in Journal of the American Academy of Child & Adolescent Psychiatry
Verified
Journal Article
Closed access
DNDouglas K. Novins
Douglas K. Novins
JSJoel Stoddard
Joel Stoddard
RARobert R. Althoff
Robert R. Althoff
ACAlice Charach
Alice Charach
SCSamuele Cortese
Samuele Cortese
BZBonnie T. Zima
Bonnie T. Zima